LipidBrick® is a unique library composed of innovative proprietary imidazolium-based cationic lipids dedicated to the formulation of lipid nanoparticles (LNPs). These active lipids safeguard mRNA molecules and enhance the transfection ability of LNPs. Each LipidBrick® lipid is permanently charged; therefore, unlike ionizable lipids, it confers an overall positive charge to LNPs, which induces extra-hepatic tropism. In addition, delivery efficacy and biodistribution can be fine-tuned by screening the LipidBrick® library to select the most suitable LipidBrick® lipid for each specific application therapeutic need.
Key Benefits:
- Efficient: Modulate LNP properties to adapt biodistribution to therapeutic goals.
- Secure: Unique structure protected by an independent patent held by Polyplus (now part of Sartorius).
- Time-Saving: In vitro and in vivo proof of concept studies have been successfully performed.
- Flexible: Versatile library for selecting the best LipidBrick® for each application.
Applications
-
ApplicationActive cationic lipids for LNP formulation
Biological Information
-
Molecule deliveredmRNA
Chemical Information
-
IUPAC/Chemical Name3-butyl-1-(2,6-dimethyl-14-octadecyldotriacontan-9-yl)-1H-imidazol-3-ium chloride.
-
Linear FormulaC59H117ClN2
Compliance Information
-
Product Documentation
-
Protocol
-
Certificate of Analysis
- Master Safety Data Sheet
-
Protocol
General Specifications
-
Amount of ReagentLipidBrick® IM21.7c 50 mg
Storage Conditions
-
Storage Conditions-20 °C ± 5 °C
Weight
-
Molecular Weight (kDa)890.03 (g/mol)